Opendata, web and dolomites

ExtremoChem

Chemically synthesised novel compounds for the stabilisation of biologics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ExtremoChem project word cloud

Explore the words cloud of the ExtremoChem project. It provides you a very rough idea of what is the project "ExtremoChem" about.

revenues    stabilise    share    wasted    proteins    effectiveness    preventing    biologic    trial    small    subject    potency    biopharmaceutical    salinity    white    neupogen    otherwise    thermally    plan    market    critical    degradation    arthritis    purification    least    size    volume    reachable    stages    synthesises    stabilization    issue    stability    direct    source    humira    carbons    tests    biopharmaceuticals    storage    material    protects    agitation    safety    sensitive    20    extremochem    blood    feasible    strict    suitable    insulins    business    stressful    biotechnology    molecules    quality    biologics    native    restored    sign    ph    vaccines    prepare    temperatures    mabs    clinical    lower    rheumatoid    compounds    medical    chain       preserve    drugs    synthetic    full    organic    once    consisting    aggregation    industrial    interferins    12    obtain    sound    assuring    savings    line    cells    medicines    degrade    biological    validation    cold    extraction    elaborate    commercial    lost   

Project "ExtremoChem" data sheet

The following table provides information about the project.

Coordinator
EXTREMOCHEM LDA 

Organization address
address: Estrada Municipal 528, 1
city: IGREJINHA
postcode: 7040-220
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://extremochem.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EXTREMOCHEM LDA PT (IGREJINHA) coordinator 50˙000.00

Map

 Project objective

Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source. Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety. Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency. Once potency is lost, it cannot be restored, this means the biologic is wasted.

ExtremoChem synthesises a line of novel compounds consisting of synthetic small organic molecules, from 8 to 12 carbons, that are able to stabilise proteins and other biological material by preventing their degradation under stressful conditions, such as higher or lower temperatures, pH, salinity, agitation under which they would otherwise degrade. eXtremochem is suitable for a wide range of proteins such as mAbs, vaccines, insulins, interferins and etc. But ExtremoChem currently focuses on mAbs, such as Humira (for rheumatoid arthritis) & Neupogen (for growth of white blood cells), since they present a high value market. The eXtremochem compounds improve the stability of molecules in the most critical purification stages and protects biologics, preventing aggregation and increasing production volume by 20%. Furthermore, eXtremochem enables long-term storage of thermally sensitive biologics without the need for cold chain, thus bringing significant savings to biopharmaceuticals – 6.5% of their revenues.

The Phase 1 project will allow ExtremoChem to evaluate the medicines’ degradation under the presence of the small organic molecules through several stabilization tests, prepare a feasible industrial scale-up plan, plan a sound Ph 1 clinical trial, elaborate the business scale up, and size the reachable market and a reliable market share. Within the overall project, ExtremoChem aims to: obtain the clinical validation and sign at least one commercial agreement.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXTREMOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXTREMOCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More